Profile data is unavailable for this security.
About the company
Santhera Pharmaceuticals Holding AG (Santhera) is a Switzerland-based company engaged in the pharmaceutical sector. The Company operates through one business segment, which is the research, development and commercialization of pharmaceutical products for the treatment of neuromuscular and mitochondrial diseases, such as Duchenne muscular dystrophy (DMD) and cystic fibrosis (CF). The Company focuses also on development of gene therapy for the treatment of LAMA2 (Laminin Subunit Alpha 2) deficient congenital muscular dystrophy (CMD). Santhera operates through its wholly owned subsidiaries: Santhera Pharmaceuticals (Schweiz) AG, Liestal, Santhera Pharmaceuticals (USA) Inc, Santhera Pharmaceuticals (Canada) Inc, Santhera Pharmaceutical (Deutschland) GmbH and Oy Santhera Pharmaceuticals (Finland) Ltd.
- Revenue in CHF (TTM)39.12m
- Net income in CHF-41.97m
- Incorporated2002
- Employees79.00
- LocationSanthera Pharmaceuticals Holding AGHohenrainstrasse 24PRATTELN 4133SwitzerlandCHE
- Phone+41 619068950
- Fax+41 619068951
- Websitehttps://www.santhera.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hyloris Pharmaceuticals SA | 7.88m | -5.91m | 163.22m | 40.00 | -- | 5.45 | -- | 20.72 | -0.2265 | -0.2265 | 0.3021 | 1.15 | 0.19 | -- | 2.01 | 209,046.00 | -14.25 | -19.78 | -16.89 | -23.43 | 97.32 | 95.47 | -74.98 | -355.75 | -- | -22.85 | 0.0636 | -- | 305.27 | 147.54 | 58.76 | -- | -24.74 | -- |
| Syncom Formulations (India) Ltd | 43.25m | 4.59m | 164.02m | 802.00 | 32.98 | 5.16 | 32.35 | 3.79 | 0.57 | 0.57 | 5.45 | 3.64 | 1.14 | 9.85 | 4.42 | -- | 12.09 | 8.56 | 15.15 | 11.58 | 34.05 | 35.18 | 10.61 | 10.15 | 3.85 | 57.70 | 0.0132 | -- | 76.55 | 17.74 | 95.28 | 28.24 | 41.62 | -- |
| Beta Drugs Ltd | 33.63m | 3.94m | 164.97m | 371.00 | 40.73 | 9.02 | 32.36 | 4.91 | 43.23 | 43.23 | 367.69 | 195.25 | 1.05 | 3.87 | 3.99 | -- | 12.29 | 14.62 | 16.87 | 20.88 | 41.50 | 40.30 | 11.71 | 12.33 | 2.64 | 8.88 | 0.4024 | -- | 22.54 | 31.89 | 16.42 | 35.13 | 19.23 | -- |
| Santhera Pharmaceuticals Holding AG | 39.12m | -41.97m | 165.64m | 79.00 | -- | 5.63 | -- | 4.23 | -3.68 | -3.68 | 3.44 | 2.17 | 0.2985 | 1.61 | 4.88 | 495,151.90 | -32.03 | -37.28 | -49.33 | -61.57 | 60.29 | 77.63 | -107.30 | -111.07 | 1.26 | -4.36 | 0.5946 | -- | -62.17 | -12.29 | -176.62 | -- | -7.99 | -- |
| Biostem Technologies Inc | 264.81m | 26.43m | 166.14m | 67.00 | 8.79 | 4.39 | 6.24 | 0.6274 | 1.43 | 1.43 | 14.27 | 2.85 | 3.41 | 8.67 | 4.40 | -- | 34.04 | -- | 121.37 | -- | 96.28 | -- | 9.98 | -- | 1.38 | 100.98 | 0.0784 | -- | 1,708.93 | -- | 475.86 | -- | -- | -- |
| Panion & BF Biotech Inc | 54.80m | 2.97m | 167.69m | 321.00 | 56.59 | 3.42 | 23.14 | 3.06 | 1.27 | 1.27 | 23.45 | 20.97 | 0.6353 | 1.78 | 10.46 | -- | 3.44 | 3.46 | 5.25 | 4.90 | 52.30 | 52.04 | 5.41 | 5.28 | 0.8218 | 14.98 | 0.2722 | 123.31 | 7.85 | 5.22 | 61.26 | -5.05 | 10.70 | 0.3601 |
| Daito Pharmaceutical Co Ltd | 273.65m | 10.31m | 168.48m | 1.07k | 16.49 | 0.5974 | 5.11 | 0.6157 | 62.82 | 62.82 | 1,664.70 | 1,734.24 | 0.6505 | 2.14 | 2.88 | -- | 2.27 | 5.12 | 2.95 | 6.67 | 17.06 | 21.75 | 3.49 | 7.35 | 1.37 | -- | 0.1858 | -- | 7.99 | 2.39 | -42.09 | -13.52 | 20.67 | -- |
Data as of Jul 11 2025. Currency figures normalised to Santhera Pharmaceuticals Holding AG's reporting currency: Swiss Franc CHF
4.89%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| UBS Asset Management Switzerland AGas of 30 Jun 2025 | 244.55k | 1.81% |
| Z�rcher Kantonalbank (Investment Management)as of 30 May 2025 | 212.65k | 1.57% |
| Valiant Bank AGas of 30 Apr 2025 | 59.98k | 0.44% |
| BlackRock Asset Management Deutschland AGas of 03 Jul 2025 | 30.31k | 0.22% |
| Dimensional Fund Advisors LPas of 04 Jul 2025 | 29.50k | 0.22% |
| Amundi Asset Management SASU (Investment Management)as of 30 May 2025 | 23.47k | 0.17% |
| Banque Cantonale Vaudoise (Investment Management)as of 31 Mar 2025 | 21.95k | 0.16% |
| Pictet Asset Management SAas of 31 Dec 2024 | 20.31k | 0.15% |
| Lombard Odier Asset Management (Switzerland) SAas of 30 Apr 2025 | 9.14k | 0.07% |
| Swiss Rock Asset Management AGas of 31 May 2025 | 8.32k | 0.06% |
More ▼
Data from 31 Mar 2025 - 03 Jul 2025Source: FactSet Research Systems Inc.
